53 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
2477546	16	Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin.	Centre De Pharmacologie-Endocrinologie (Montpellier, France)
3336026	18	Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines.	Merck Sharp & Dohme Research Laboratories
2441054	18	Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.	TBA
3761313	22	Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility.	TBA
27876250	60	Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH	Jagiellonian University Medical College
26988801	55	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.	Jagiellonian University Medical College
26654202	99	Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.	Mayo Clinic
25862198	52	Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.	Mayo Clinic
17933530	1	SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.	Johnson & Johnson Pharmaceutical Research And Development
8978852	10	Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.	Glaxo Wellcome Research And Development
8558528	16	Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist"trigger".	Glaxo Wellcome
8709137	14	3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists.	Glaxo Wellcome Research And Development
7650691	14	Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands.	Glaxo Research Institute
19815410	23	Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.	Johnson & Johnson Pharmaceutical Research And Development
19811913	52	Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.	Johnson & Johnson Pharmaceutical Research And Development
19271701	4	Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.	Mayo Clinic
17536796	106	Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.	James Black Foundation
8709093	21	3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents.	Glaxo Wellcome Research And Development
7837233	21	CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).	Glaxo Research Institute
22424974	35	Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists.	Pfizer
20547453	122	Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain.	University Of Arizona
18176998	45	Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.	Abbott Laboratories
16509592	101	Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.	University Of Arizona
13678399	54	Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes.	University Of Arizona
8340909	14	Excursions in drug discovery.	Merck Research Laboratories
2848124	401	Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.	Merck Sharp & Dohme Research Laboratories
	16	Conversion of acyclic nonpeptide CCK antagonists into CCK agonists	Glaxo Wellcome Research And Development
21728335	20	New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).	University Of Trieste
21456601	26	Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.	University Medical Centre Ljubljana
21493064	69	Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.	Merck
20851601	28	Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.	Pfizer
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical And Public Health Institute
20591666	66	A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.	Università
19592244	61	7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists.	Novartis Institutes Of Biomedical Research
	10	1,4-Benzodiazepin-2-one derived neurokinin-1 receptor antagonists	TBA
	25	Synthesis and biological activity of 1-alkylcarbonylmethyl analogues of YM022	TBA
	7	The design of a dipeptide library for screening at peptide receptor sites	TBA
	15	Tryptophan-norleucine 1,5-disubstituted tetrazoles as cis peptide bond mimics: Investigation of the bioactive conformation of a potent and selective peptide for the cholecystokinin-B receptor	TBA
18684621	59	2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.	Merck
18614364	109	Discovery of imidazole carboxamides as potent and selective CCK1R agonists.	Merck Research Laboratories
9722499	3	Recent natural products based drug development: a pharmaceutical industry perspective.	Bristol-Myers Squibb Pharmaceutical Research Institute
17562367	10	Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor.	Istituto Di Biostrutture E Bioimmagini-Cnr
17201419	93	Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.	University Of Arizona
17034143	88	Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.	Johnson And Johnson Pharmaceutical Research And Development
16722631	87	An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.	Predix Pharmaceuticals
16610788	5	Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their"receptor desmodynamic processes".	University Of Naples Federico Ii
16033264	48	Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor.	Instituto De QuíMica MéDica (Csic)
8411002	67	Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties.	University Of Paris
1501220	52	Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.	Abbott Laboratories
1495013	24	N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity.	Hadassah-University Hospital
1433225	18	Analogs of CCK incorporating conformationally constrained replacements for Asp32.	Roche Research Center